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Summary
A novel G8363A mutation in the mtDNA tRNALYS gene
was associated, in two unrelated families, with a syn-
drome consisting of encephalomyopathy, sensorineural
hearing loss, and hypertrophic cardiomyopathy. Muscle
biopsies from the probands showed mitochondrial pro-
liferation and partial defects of complexes I, m11, and IV
of the electron-transport chain. The G8363A mutation
was very abundant (>95%) in muscle samples from the
probands and was less copious in blood from 18 mater-
nal relatives (mean 81.3% ± 8.5%). Single-muscle-fiber
analysis showed significantly higher levels of mutant ge-
nomes in cytochrome c oxidase-negative fibers than in
cytochrome c oxidase-positive fibers. The mutation was
not found in >200 individuals, including normal con-
trols and patients with other mitochondrial encephalo-
myopathies, thus fulfilling accepted criteria for pathoge-
nicity.
Introduction
Mitochondrial encephalomyopathies are a heteroge-
neous group of disorders that differ widely in their clini-
cal features but have in common functional-and, less
consistently, morphological- abnormalities of muscle
mitochondria. Genetic analysis has revealed numerous
pathogenic mtDNA mutations during the past 7 years,
including large-scale rearrangements and >30 point mu-
tations in tRNA or protein-coding genes (Schon et al.
1994).
Despite this remarkable progress, many patients with
mtDNA mutations probably remain undiagnosed.
Multisystem clinical involvement, maternal inheritance,
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and "soft" signs in maternal relatives, such as short
stature, diabetes, or migrainelike headache, are useful
clues for recognizing diseases associated with mtDNA
defects (Wallace 1992; DiMauro and Moraes 1993). In
muscle biopsies, morphological evidence of mitochon-
drial proliferation (i.e., ragged red fibers [RRF]), often
associated with scattered cytochrome c oxidase-nega-
tive (COX-) fibers, or combined biochemical defects of
respiratory-chain complexes may further suggest that
the mutations affect regions directly involved in mtDNA
protein synthesis, such as the 22 tRNA genes (Moraes
et al. 1993).
We have used SSCP analysis and direct DNA sequenc-
ing of all 22 tRNA genes to detect putative mtDNA
mutations in nine patients who had clinical, biochemi-
cal, or morphological features of multiorgan involve-
ment, affecting especially tissues that depend heavily on
oxidative metabolism, such as brain and heart. Here,
we describe two unrelated families with similar clinical
presentations, characterized by maternally inherited car-
diomyopathy (MICM) and hearing loss in multiple fam-
ily members. Sequence analysis of mtDNA showed a
novel G8363A transition in the tRNALYS gene.
Patients, Material, and Methods
Family A
Case 111-3.-Case 111-3, the proband in family A (fig.
1A), was a Hispanic 16-year-old man who developed
normally until age 8 years, when he presented with heart
failure and cognitive regression. Cardiological examina-
tion was compatible with dilated cardiomyopathy, and
neurological examination showed sensorineural hearing
loss, ophthalmoparesis, ataxia, and muscle weakness.
His clinical course worsened progressively, and he died
at age 17 years, of cardiorespiratory arrest. Autopsy
was not performed. Family history was remarkable for
several maternal relatives who suffered from similar
symptoms, as described below.
Case 1-1.-Case I-1, the maternal grandmother, is in
her 70s. Clinical examination revealed sensorineural
hearing loss, mild truncal ataxia, and sensory loss sug-
gestive of peripheral neuropathy.
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Figure 1 Pedigrees of family A (panel A) and family B (panel B). Numbers are percentages of mutated genomes in blood samples in all
subjects except the probands, in whom they represent means of muscle and blood mutant mtDNAs.
Case II-1--Case II-1 was the proband's maternal
aunt. She became symptomatic at age 7 years, with un-
specified progressive heart complaints, and died sud-
denly at age 14 years
Case II-2.-Case 11-2 was the proband's mother. Car-
diac complaints dated to her 20s, when she first noted
exertional dyspnea and premature fatigue. At that time,
she had increased levels of blood lactate and pyruvate.
A muscle biopsy did not show RRF, but electron micros-
copy showed abnormal mitochondria with paracrystal-
line inclusions. She died at age 33 years, of cardiac
failure.
Case 11-3.-Case 11-3, a 40-year-old woman, is asymp-
tomatic.
Case 11-4.-Case II-4, is a woman in her late 30s, in
whom clinical examination revealed sensorineural hear-
ing loss and mild cerebellar ataxia
Case II-7.--Case II-7, the proband's uncle, is in his
20s and has recently started complaining of hearing
problems. He has not yet received full neurological or
cardiological evaluation
Case 111-1.-Case 111-1, the proband's half-sister, is a
14-year-old girl with progressive external ophthalmo-
paresis (PEO), sensory peripheral neuropathy, and un-
specified "cardiac problems."
Case 111-2.-Case III-2 is a 15-year-old girl with PEO
and shortness of breath after mild physical exertion. She
has not yet received complete cardiological evaluation
Case 111-4.-Case 111-4 is a 5-year-old boy who devel-
oped normally until age 4 years, when weakness and
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toe walking started. Neurological examination showed
weakness of the pelvic girdle, hyperreflexia, ataxia, and
mild developmental delay. Echocardiogram revealed hy-
pertrophic cardiomyopathy. Ultrastructural examina-
tion of muscle showed both an increased number of
mitochondria under the sarcolemma and increased lipid
droplets in some muscle fibers.
Case 111-5.-Case III-5 is mildly mentally retarded
Case 111-6.-Case 111-6 is apparently healthy.
Family B
Case 11-1.-Case II-1, the 44-year-old African Ameri-
can proposita (fig. 1B), was healthy until age 35 years,
when she first noted progressive hearing loss. At age 37
years she developed slurred speech, gait difficulties with
leg pain and heaviness, and shortness of breath after
mild exercise. Physical examination showed "horse col-
lar" lipomas and increased fat tissue distributed in folds
on the lateral aspects of the chest and abdomen. The
thighs appeared thin, but the legs showed mild bilateral
calf hypertrophy. Neurological examination revealed bi-
lateral sensorineural hearing loss, mild proximal limb
weakness, predominantly in the legs, and slight dysmet-
ria. Neither seizures nor myoclonus was noted. Cardiac
complaints dated to her 30s, but more recently she has
complained of frequent chest pain, with mildly elevated
blood pressure. Cardiological examination, electrocar-
diogram, and echocardiogram were suggestive of cardio-
myopathy. A thallium scintigraphy done in both vertical
and horizontal long-axis and short-axis modes showed
an irregular thallium uptake consistent with left-ventric-
ular hypertrophy, involving especially the free wall. Se-
rum creatine kinase (CK) levels were eight times normal,
with a CK-MB fraction of 3.8%, consistent with myo-
cardial involvement. Venous lactate was elevated (2.5
mM; normal <1.8 mM) and increased excessively after
exercise (to four times normal). Electromyography
showed myopathic features. Muscle biopsy revealed sev-
eral RRF and COX- fibers, and electron microscopy
showed an increased number of mitochondria under the
sarcolemma and between myofibrils with frequent para-
crystalline inclusions.
Case 1-1.-Case I-1, the proband's mother, had died
at age 62 years, because of "intestinal pseudo-obstruc-
tion." Past medical history had been remarkable for un-
specified myocardial problems, gait difficulties, and
hearing loss by age 50 years. The proposita's brothers
(II-2, 11-3, and II-4) are asymptomatic, but the youngest
sister (11-5) has a "large heart."
Case 111-1.-Case III-1, the eldest daughter of this fam-
ily's proband, developed seizures during a febrile epi-
sode at age 5 years. Around that time, she experienced
left foot drop, with frequent falls, when she attempted
to run. In subsequent years her symptoms worsened.
At age 24 years, she complains of slurred speech, gait
instability, exercise intolerance, and myalgia during
walking or climbing stairs. Blood venous lactate was
mildly elevated. Psychological evaluation showed bor-
derline mental retardation. Her 3-year-old son (IV-1)
has a history of failure to thrive, developmental delay,
congenital heart disease, and mental retardation. He re-
cently started complaining of hearing impairment.
Case III-2.--Case III-2, the twin sister of III-1, has
severe mental retardation and congenital hypertrophic
cardiomyopathy. Blood venous lactate is 2.7 mM/liter,
and serum CK levels are three times normal (MB frac-
tion 2.8%, consistent with myocardial involvement). A
recent audiometry showed severe neurosensory hearing
loss.
Case III-3.-Case III-3 has hyperthyroidism.
Case 11-4.--Case III-4 is mentally retarded, and par-
ents report "abnormal behavior."
Case 11-5.--Case III-5, the twin sister of III-4, is ap-
parently healthy
Material and Methods
Respiratory-chain enzymes and citrate synthase activi-
ties were measured spectrophotometrically in 10% mus-
cle extracts, as described elsewhere (DiMauro et al.
1987). Suitable RFLP and Southern blot analyses were
used to rule out the presence of known pathogenic
mtDNA mutations and large-scale rearrangements (Zev-
iani et al. 1988; Ciafaloni et al. 1992; Silvestri et al.
1993a; Santorelli et al. 1994). In particular, we excluded
the typical mtDNA mutations associated with MELAS
(mitochondrial encephalomyopathy, lactic acidosis, and
strokelike episodes); MERRF (myoclonus epilepsy with
RRF); maternally inherited Leigh syndrome; neurogenic
muscle weakness, ataxia, and retinitis pigmentosa; and
Leber hereditary optic neuropathy (Schon et al. 1994).
We used a combination of PCR-SSCP (Suomalainen
et al. 1992) and direct DNA sequencing of the 22 tRNA
genes to search for new mutations. Approximately 200
ng of total DNA were amplified by PCR (1 min at 94°C,
1 min at 55°C, 1 min at 72°C, for 25 cycles), and a last
"hot-PCR cycle" was performed in the presence of [a-
32p] dATP. Oligonucleotide primers were as described
elsewhere (Moraes et al. 1993). PCR products were
boiled for 2 min. loaded onto a 0.5 x MDE 1% glycerol
gel, and electrophoresed for 14 h at room temperature.
The gel was dried and subjected to autoradiography for
18 h at room temperature. Direct sequencing of abnor-
mal fragments, as well as of the two mtDNA-encoded
ATPase genes (ATPase 6 and 8), was performed by use
of the "ds DNA cycle sequencing kit" (Gibco BRL).
We employed a mispaired PCR method to screen for
the novel G8363A mutation. A mismatched (5'-3')
8341-8361 forward primer (mismatched G at np 8360)
was used in combination with a backward primer (5'-
3') 8582-8561 to PCR amplify a 240-bp fragment,
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Figure 2 RFLP analysis of the G8363A mutation in members
of family A. Subjects are as in fig.1A. A 240-bp PCR-amplified frag-
ment is normally cut by the endonuclease HphI (GGTGAN8/N7) into
four fragments, of 113, 53, 44, and 30 bp. The G8363A mutation
abolishes a site of cut, reducing the number of fragments to three
(113, 83, and 44 bp).
which was later cleaved with the restriction enzyme
HphI (GGTGA8/7). While the normal sequence yields
four fragments, the presence of the mutant A8363 abol-
ishes a site of cut, thus reducing the number of fragments
to three (fig. 2).
To estimate the percentage of mutant mtDNAs, we
added [a-32P]dATP only in the last PCR cycle and elec-
trophoresed the digestion products through a 12% non-
denaturing polyacrylamide gel. Fragment intensities
were measured by use of a Betascope 603 blot analyzer
(Betagen).
Single muscle fibers were isolated and subjected to
PCR amplification as described elsewhere (Moraes et
al. 1992). RFLP analysis was performed as described
above.
Previously described methods (Masucci et al. 1995)
were employed for total RNA extraction from muscle
and skin fibroblasts in subject III-4 from family A, RNA
separation in 1.4% agarose gels, blotting onto nylon
membrane, and hybridization to [a-32P]dATP-labeled
probes prepared by PCR for ND1, ND5, COX subunits
I and II, and A 8/6 (ATP synthase subunits 8 and 6).
Either an 18S rRNA or a P-actin probe was used to
normalize the amount of RNA blotted for each sample.
Results
Biochemical studies were performed in muscle ex-
tracts from the two probands and from case III-4 in
family A. The activities of electron transport-chain
complexes containing mtDNA-encoded subunits were
decreased in all three specimens, suggesting a general
impairment of mitochondrial protein synthesis (table 1).
Having ruled out large-scale rearrangements and the
most common pathogenic point mutations in mtDNA,
we used a combination of SSCP and direct sequencing
to search for novel mtDNA mutations in the 22 tRNAs.
We found a new tRNALYs mutation, a G8363A substitu-
tion, in both families (fig. 3). RFLP analysis showed
that the mutation was very abundant (>95%) in muscle
from the probands and in muscle and skin fibroblasts
from a severely affected maternal cousin but that it was
also present, in lesser amounts (mean 81.3 ± 8.5%,
range 59%-94%), in blood from 17 maternal relatives
(figs. 1 and 2). This newly recognized mutation was not
present in >200 individuals of different ethnic back-
grounds, including 40 controls with other neuromuscu-
lar disorders or mitochondrial encephalomyopathies.
To determine the threshold levels for phenotypic ex-
pression, we quantitated mutant and wild-type mtDNAs
in single muscle fibers from the proband in family B,
using a PCR-based method (Sciacco et al. 1994). Fibers
were divided into two groups, COX' (n = 34) and
COX- (n = 26). There were no differences between the
two group of fibers, in the total amount of amplified
mtDNA. Although muscle tissue as a whole harbored
high percentages of mutant genomes, mutant mtDNA
was significantly more abundant in COX- fibers (93.8
± 2.6) than in COX' fibers (90.8 ± 4.1) (t = 3.4; df
= 58; P < .05). Northern blots showed neither gross
qualitative or quantitative abnormalities in the tran-
scripts studied nor any extra bands (data not shown).
Discussion
Mitochondrial diseases have been known for 30 years,
since Luft's first description of a patient suffering from
"nonthyroidal hypermetabolism" (Luft et al. 1962).
However, the pathogenic importance of mtDNA muta-
tions has been fully revealed only during the past 7 years
(Schon et al. 1994). Awareness of the extreme clinical
heterogeneity associated with mtDNA mutations, in-
creased attention to maternal inheritance, and availabil-
ity of effective molecular genetic screening contribute to
explain the large number of pathogenic mtDNA muta-
tions identified during the past few years (DiMauro and
Moraes 1993). Nevertheless, there are cases in which
specific mutations have not been found, even though
clinical presentation or family history was suggestive of
a mtDNA defect. Undoubtedly, additional pathogenic
mutations remain to be identified, as documented by the
present study.
We investigated nine patients from two unrelated fam-
ilies with heterogeneous clinical presentation: five had
multiorgan involvement, including brain, muscle, and
heart; maternally inherited hearing loss was the predom-
inant feature in one patient; and cardiomyopathy and
retinal degeneration dominated the clinical picture in
another individual. Family history was positive for ma-
ternal inheritance, and both laboratory findings and
morphological or biochemical studies of muscle were
suggestive of disorders due to mtDNA mutations and
of altered protein synthesis. We combined PCR-SSCP
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Table 1
Respiratory-Chain Enzyme Activities (mmol/min/mg Protein) in Muscle Homogenates
Complex Complexes Complexes Complex
IV I + III II + III II CS
Patient 111-3 (family A) 1.32 .78 .53 1.4 18.92
Patient III-5 (family A) 1.76 .75 .45 1.2 21.45
Patient III-2 (family B) 1.30 .85 .67 2.4 15.83
Controls (n = 38) 2.8 + .52 1.02 + .38 .70 + .23 1.00 + .53 9.88 + 2.55
and direct sequencing to search for novel mutations in
mtDNA genes involved in protein synthesis, starting
with the 22 tRNAs.
SSCP and sequence analysis revealed several novel
mutations in tRNA genes. This was not surprising, be-
cause the mitochondrial genome has a high mutation
rate, leading to the establishment of numerous neutral
polymorphisms. Therefore, we evaluated the potential
pathogenicity of each mutation, on the basis of the fol-
lowing criteria: the mutation should (i) affect an evolu-
tionarily conserved nucleotide, (ii) be heteroplasmic, at
least in some family members, and (iii) be absent in a
large series of controls of different ethnic origin. These
minimal criteria are generally accepted and were suffi-
cient to exclude from further consideration all but one
mutation: a G8363A transition in the tRNALYs gene,
which affected a conserved residue, was present in high
percentage (>95%) in the two propositi, occurred less
abundantly in less affected relatives, and was not found
in normal individuals. In addition, the same mutation
caused similar clinical presentation in two apparently
unrelated families. Sequence analysis of the highly poly-
morphic D-loop region of mtDNA failed to show any
maternal relationship between the propositi of the two
families, but we are performing complete haplotyping
of the two families, to formally exclude any relationship.
The spectrum of clinical features observed in these
two families is rather broad, including encephalomyopa-
thy, PEO, sensorineural hearing loss, ataxia, cardiomy-
opathy, and hyperthyroidism. Although some of these
features are seen in more common mtDNA disorders,
such as MERRF and MELAS, the association of cardio-
A
Aminoacyl c - a -*A
Acceptor Stem A -T nt 8363C -G
T -A
G -C
T -A
A -T AC
A A T T C T C AI A TT
DHEU A A T CG A AGAG C loopC I' ACloop TT A'G C A T ACqT T-A A
A-T G
C-T
C-G
C A
T A
T TT
Anticodon
loop
8363
ACTGTAAAGCTAAC-------TTAGCATTAACCTTTTAAGTTAAAGATTAAGAGAACCAACACCTCTTTACAGT G A
ACTGTAAAGCTAAC-------TTAGCATTAACCTTTTAAGTTAAAGATTAAGAGAACCAACACCTCTTTACAGT A A
ACTAAGAAGCTAT--------ATAGCACTAACCTTTTAAGTTAGAGATTGAGAG--CCATATACTCTCCTTGGT G A
ATTGCGAAGCTT---------AGAGCGTTAACCTTTTAAGTTAAAGTTAGAGACAA-CAA---ATCTCCACAAT G A
ACTATGAAGCTA---------AGAGCGTTAACCTTTTAAGTTAAAGTTAGAGACCTTAA--A-ATCTCCATAGT G A
ACTAAGAAGCTAAAT-GGGCATTAGCGACAGCCTTTTAAGCTGTAGATTGGTGACTCCCA-A-CCACCCTTAAT G A
ATTAAGAAGCTATGCACC-----AGCACTAGCCTTTTAAGCTAGAGAGAGGGGACACCCT---CCCCCCTTAAT G A
ACTAAGAAGCTAATATGGGTTA-AGCACCAGCCTTTTAAGCTGGAAGCAGGTGACTCCCAA--CCACCCTTAAT G A
CTTAATTAGCTTATTT-----AAAGCTTTAGACTCTTAATTTAAAAGAAATTAGCTAATAC--CTATTATTAAG G A
ATTAGATGACTGAAAG-----CAAGTACTGGTCTCTTAAACCATATAATAGTAAATTAGC-CATTACTTCTAAT G A
Cloverleaf of the mitochondrial tRNALys. The position of the novel mutation (arrow) and homology with other species are also
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shown.
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myopathy and hearing loss in several generations in
these two families distinguishes the syndrome from
other mtDNA-associated disorders. Preferential involve-
ment of these two organs is not surprising, because tis-
sues with high oxidative metabolism, such as heart and
cochlea, are particularly vulnerable to impaired mito-
chondrial function. Cognitive impairment was also pres-
ent in several members of these pedigrees, probably be-
cause of impaired cerebral oxidative metabolism.
The G8363A mutation identified in these families rep-
resents the third putative pathogenic mutation found in
the tRNALYS gene; the other two are associated with
MERRF (DiMauro and Moraes 1993). However, if one
accepts strict clinical criteria for the diagnosis of
MERRF (Silvestri et al. 1993a), neither one of our pro-
bands would fit this definition.
Additional evidence in favor of the pathogenic nature
of the G8363A mutation emerges from the following
considerations. First, this new mutation abolishes a
highly conserved pairing in the aminoacyl stem of the
tRNALYS, which might disturb the double helix of the
stem and alter the overall secondary structure of the
molecule. In particular, the absence of a hydrogen-
bonded base pair at the end of the acceptor stem is likely
to impair both the activity of peptidyl-tRNA hydrolase,
an enzyme of the translational apparatus (Dutka et al.
1993), and the correct attachment of amino acids to
their cognate tRNA by amynoacyl-tRNA synthetase
(Jahn et al. 1991; Saks et al. 1994). It is of interest that
a change in a similar position occurs in the C3303T
mutation in the tRNALeu(UUR) gene, a mutation that is
also characterized by maternally inherited cardiomyopa-
thy (Silvestri et al. 1993b).
Second, single-fiber PCR analysis suggested a signifi-
cant correlation between abundance of mutant mtDNA
and biochemical abnormality, as has been found for
other mtDNA mutations (Moraes et al. 1992). However,
the threshold level of mutant mtDNA needed for bio-
chemical and clinical phenotypes to become manifest
was very high. It is, therefore, conceivable that other
factors, including different nuclear and mitochondrial
genetic backgrounds, might modulate phenotypic ex-
pression. These factors might contribute to explain the
different clinical expression among different members
in the two families.
The partial and multiple defects of oxidative phos-
phorylation (OXPHOS) metabolism observed in muscle
biopsies from the probands suggest that the G8363A
mutation causes a general impairment of mitochondrial
protein synthesis. The relative content of lysine in differ-
ent respiratory-chain subunits may explain the preferen-
tial involvement of complex I and complex IV, shown
in MERRF patients and in this study, because lysine
residues are more abundant in NDS, ND2, and COX I.
However, in addition to decreases in the rates of synthe-
sis and in steady-state levels of mitochondrial polypep-
tides, the MERRF mutations have been also associated
with abnormal translation products (Yoneda et al. 1994;
Masucci et al. 1995). We are now investigating the pres-
ence of similar abnormal peptides in skin fibroblasts
from a patient with the G8363A mutation.
The same mutation produced similar clinical manifes-
tations in two unrelated families, and there was a rea-
sonable correlation between percentage of mutant
mtDNA and clinical severity, though not as striking as
we have observed in MELAS (Hirano and Pavlakis
1994). For example, patients II-3 and 11-7 in family A
and patient 111-5 in family B, who harbored lower
amounts of mutant genomes, were less severely affected
than the probands. However, we did not study tissues
other than blood, in most maternal relatives; therefore,
it is possible that higher percentages of mutant genome
are present in affected tissues, such as heart in case III-
2 in family B. Finally, pathogenicity is supported by the
simultaneous report, by an independent group (Ozawa
et al. 1995), of the G8363A mutation in affected families
of different ethnic origin.
Clinical examination of additional affected and
asymptomatic individuals from our families, as well as
generation of transmitochondrial cybrids (King and At-
tardi 1989), may give us better insight on the preferential
tissue involvement and may clarify the deleterious effects
of the G8363A mutation on OXPHOS metabolism. Our
findings add to the evidence of genetic heterogeneity
underlying familial deafness syndromes and MICM (Ca-
sali et al. 1995). Whether these syndromes occur inde-
pendently or in combination, mtDNA mutations should
be considered in differential diagnosis, particularly when
there is evidence of maternal inheritance. Although accu-
rate molecular diagnosis may not immediately affect
prognosis or treatment, it is of crucial importance for
genetic counseling.
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